PMID- 35909401 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220801 IS - 0253-8253 (Print) IS - 2227-0426 (Electronic) IS - 0253-8253 (Linking) VI - 2022 IP - 2 DP - 2022 TI - SCIG administration: A promising and patient convenient alternative for those receiving long-term IVIG. PG - 29 LID - 10.5339/qmj.2022.fqac.29 [doi] LID - 29 AB - BACKGROUND: Intravenous immunoglobulin (IVIG) therapy has been used as antibody replacement therapy in primary immunodeficiency diseases (PID) for more than 50 years. In this study, we aimed to define IVIG usage and adverse reactions and complications in PID and explain how subcutaneous immunoglobulin (SCIG) replacement therapy is an alternative that improves the patient experience. In addition, the additional nursing responsibilities associated with this service were also identified. METHODS: Data and service satisfaction surveys for the last 10 years were reviewed from the Allergy and Immunology Division log registry for those on IVIG and SCIG. RESULTS: IVIG practice: Most patients currently on IVIG in our unit have PID. Adverse reactions occur during the initial 30 to 60 minutes of the infusion and are mild and self-limited. Infusion reactions are more likely to occur in patients receiving IVIG for the first time. Infusion-related complications included pyrogenic reactions, allergic reactions, and vasomotor symptoms. Complications reported in the literature such as the transmission of blood-borne pathogens and other serious complications, including thrombotic events, renal adverse events, and aseptic meningitis were never reported. Pyrogenic reactions occurred at a rate >/= 100 mL/hr in at least 3 patients, and a slower infusion rate of